Brief: HLS Therapeutics Announces Q4 2020 Financial Results
18/03/2021 10:35
March 18 (Reuters) - HLS Therapeutics Inc HLS.TO :
* Q4 2020 REVENUE WAS $16.5 MILLION VERSUS $13.9 MILLION IN
Q4
2019
* QTRLY NET LOSS PER SHARE $0.23
* Q4 REVENUE VIEW $16.2 MILLION -- REFINITIV IBES DATA
Source text for Eikon: ID:nCNWZbtJla
Further company coverage: HLS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on HLS Therapeutics
See all newsBrief: Hls Therapeutics Increases Normal Course Issuer Bid
Brief: HLS Therapeutics Announces Q2 2026 Financial Results
Canada's HLS Therapeutics Q2 revenue rises on higher cardiovascular drugs demand
Brief: HLS Therapeutics - Secures Nilemdo Reimbursement With Private Payers Covering 80% Of Privately Insured Canadians
Canada Research Roundup: CIBC ,HLS Therapeutics, TD Bank Group